Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

ECOG-ACRIN EA5191

Trial Overview

Official Title

Testing the Addition of the Pill Chemotherapy, Cabozantinib, To the Standard Immune Therapy Nivolumab Compared To Standard Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer

Study Purpose

To compare the two investigational treatments (cabozantinib alone to using cabozantinib plus the usual treatment nivolumab) to the current standard of care second line therapy

Diagnosis

Patients have advanced non-squamous non-small cell lung cancer that has grown or has recurred.

Eligibility

Stage IV NSCLC

Patients must have non-squamous

ECOG 0-1, known ROS1, RET, MET alterations, at least 1 prior therapy

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

This study has a screening step, the purpose of this step is to test your tumor to find out if it has a specific molecular alteration. This study has 3 randomized study groups.

  • Group A: Patients will get the investigational pill therapy being studied, cabozantinib.
  • Group B: Patients will get the investigational pill therapy being studied, cabozantinib, plus immunotherapy, nivolumab.
  • Group C: Patients will get the standard chemotherapy regimen used to treat this type of cancer.

For more information, visit ClinicalTrials.gov

Key Participation Requirements
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
EA5191